HVCN1 (Hydrogen voltage-gated channel 1) is the only mammalian voltage-gated proton channel. In human B lymphocytes, HVCN1 associates with the B-cell receptor (BCR) and is required for optimal BCR signaling and redox control. HVCN1 is expressed in malignant B cells that rely on BCR signaling, such as chronic lymphocytic leukemia (CLL) cells. However, little is known about its regulation in these cells. We found that HVCN1 was expressed in B cells as two protein isoforms. The shorter isoform (HVCN1 S ) was enriched in B cells from a cohort of 76 CLL patients. When overexpressed in a B-cell lymphoma line, HVCN1 S responded more profoundly to protein kinase C-dependent phosphorylation. This more potent enhanced gating response was mediated by increased phosphorylation of the same residue responsible for enhanced gating in HVCN1 L , Thr 29 . Furthermore, the association of HVCN1 S with the BCR was weaker, which resulted in its diminished internalization upon BCR stimulation. Finally, HVCN1 S conferred a proliferative and migratory advantage as well as enhanced BCR-dependent signaling. Overall, our data show for the first time, to our knowledge, the existence of a shorter isoform of HVCN1 with enhanced gating that is specifically enriched in malignant B cells. The properties of HVCN1 S suggest that it may contribute to the pathogenesis of BCR-dependent B-cell malignancies.
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proton currents | chronic lymphocytic leukemia | Hv1 | gating kinetics | phosphorylation T he voltage-gated proton channel HVCN1 (or H V 1 or VSOP) is a small protein that conducts protons across membranes selectively (1, 2) and in a regulated manner. Previously, we described its function in B lymphocytes, where proton channels sustain B-cell receptor (BCR) signaling via regulation of reactive oxygen species production by the NADPH oxidase enzyme complex (3) . In addition, we found HVCN1 to be directly associated with the BCR. Upon receptor stimulation, the BCR and HVCN1 were cointernalized to late endosomal/lysosomal organelles called "MIICs," or MHC class II-containing compartments, where antigens bound to the BCR are digested into small peptides and loaded onto MHC class II molecules for presentation to T cells (3) .
HVCN1 is expressed not only by normal but also by malignant B cells, such as those in chronic lymphocytic leukemia (CLL) (3) . CLL cells are characterized by their reliance on BCR signaling for survival and growth (4), so it is possible that they maintain or upregulate HVCN1 expression to sustain their growth. Other tumor cells, such as those in breast (5) and colorectal cancer (6) , have been found to rely on HVCN1 for survival. In these tumor cells, proton channels prevent excessive acidification of the cytoplasm and allow increased cell migration. In malignant B cells, HVCN1 may regulate intracellular pH and at the same time sustain BCR signaling. However, its precise roles remain to be elucidated.
We show here that CLL cells and other B-cell lines specifically express higher levels of a shorter isoform of HVCN1, HVCN1 S . We identified the existence of two distinct isoforms of relatively similar size when immunoblotting B-cell lysates with an HVCN1specific antibody (3) . HVCN1 S is only weakly expressed in normal B cells, and in light of its apparent upregulation in tumor cells, we set out to characterize its function. We show that HVCN1 S responds more strongly to phosphorylation by protein kinase C (PKC) and identify the phosphorylation site. We provide evidence that HVCN1 S in B cells is preferentially expressed at the plasma membrane, even upon BCR stimulation and subsequent internalization, due to a weaker association with the BCR. Finally, we show that HVCN1 S expression results in stronger BCR signaling, increased proliferation, and augmented chemokine-dependent migration. Overall, our data indicate that HVCN1 S is an alternative protein isoform that mediates stronger currents upon PKC phosphorylation, is more highly expressed at the plasma membrane, and can confer a growth advantage to malignant B cells.
Significance
B lymphocytes are crucial cells in immune responses. Their activity is regulated by signaling pathways involving reactive oxygen species (ROS). Voltage-gated proton channels modulate B-cell responses by facilitating production of ROS. Here we compare the full-length proton channel HVCN1 L with a shorter protein isoform, HVCN1 S , which lacks the first 20 amino acids. Cells with HVCN1 S display enhanced proton currents upon stimulation. In addition, HVCN1 S is internalized to a lesser extent by interactions with the B-cell receptor, resulting in greater plasma membrane expression. Finally, HVCN1 S expression results in greater proliferation and migration. Compared with normal B lymphocytes, HVCN1 S expression is higher in B-cell lines and in B cells from patients with chronic lymphocytic leukemia, where it may contribute to disease pathogenesis. 
Results
Identification of an HVCN1 Isoform Enriched in Malignant B Cells. We investigated HVCN1 expression in a panel of B-cell lines and noted the presence of two bands of similar molecular weight. Some cell lines appeared to express more of the shorter isoform, whereas the Burkitt cell line Raji expressed it exclusively ( Fig.  1A , Left). Peripheral blood B cells expressed this short isoform (here called HVCN1 S ) at much lower levels compared with CLL cells (Fig. 1A , Center and Right).
When we started this study, the GenBank database reported only one viable splicing variant for human HVCN1 (SI Appendix, Fig. S1 , variant 1). Given the presence of an ATG 60 base pairs (bp) downstream from the first ATG, we set out to investigate if a shorter isoform could be the result of translation from this alternative start site. To this end, we expressed recombinant HVCN1 Long (HVCN1 L ) in an in vitro translation assay ( Fig. 1B, Left) . We then mutated the first ATG to TTG, which resulted in significantly reduced translation from this codon ( Fig. 1B, Center) . A shorter protein was expressed from the mutated plasmid ( Fig. 1B , Center) when expressed in whole cells also (Fig. 1C, Right) , indicating that the second ATG functioned as a start codon.
More recently, three splicing variants for human HVCN1 have been reported (SI Appendix, Fig. S1 ). Variant 1 and 2 differ in the use of alternative 5′-untranslated regions (UTRs) but code for the same full-length HVCN1 protein, whereas variant 3 uses the same 5′-UTR as variant 1 but it does not possess the first coding exon. Therefore, variant 3 lacks the first ATG and consequently translation can start only from the second ATG 60 bp downstream. To test the existence of the three mRNA variants, we designed specific PCR primers and tested them with mRNA from the cell line HBL1. We used the same reverse primer and specific forward primers for variants 1/3 and 2, annealing on their respective 5′-UTRs. To distinguish variants 1 and 3, we relied on differences in the band size of the amplified PCR product (433 for variant 1 and 393 for variant 3). As Fig. 1C , Left, shows, the PCR with primers for variant 2 and all variants produced bands of the expected sizes. For variants 1 and 3, we ran a gradient PCR (Fig. 1C, Right) , which showed the expected bands of 433 and 393 bp (Fig. 1C , arrows). Overall, our results indicate the existence of three distinct mRNA variants and therefore suggest that HVCN1 S is the result of alternative mRNA splicing, which produces a protein identical to the long isoform but lacking the first 20 amino acids.
To confirm the nature of this shorter isoform, we raised an antibody toward the first 20 amino acids of HVCN1, which should recognize the long isoform only. Our original anti-HVCN1 antibody, which recognizes a region in the N terminus closer to the first transmembrane domain (amino acids 26-46), detected both isoforms in CLL cells ( Fig. 1D , Left). Also, recombinant HVCN1 L and HVCN1 S were both detected. In contrast, an immunoblot with the anti-HVCN1 L -specific antibody detected only the long isoform, both recombinant and endogenously expressed (Fig. 1D, Right) . These results confirmed that the shorter isoform of HVCN1 is a protein with a shorter N terminus domain, lacking the first 20 amino acids.
Both Isoforms Are Voltage-Gated Proton Channels. Biophysical properties of HVCN1 L and HVCN1 S were compared in transduced LK-35.2 cells using the whole-cell voltage-clamp configuration over a wide range of pH. The H + currents generated by the two isoforms appeared generally similar. SI Appendix, Fig.  S2A , confirms that both isoforms were proton selective because the reversal potential for current (V rev ) was close to the Nernst potential for H + (E H ). This result is expected because the selectivity filter is in the middle of the S1 transmembrane helix (1), far from the N terminus where the two isoforms differ.
A unique property of all known voltage-gated proton channels crucial to their function is ΔpH-dependent gating (2, 7) . The position of the proton conductance-voltage (g H -V) relationship depends strongly on both pH o and pH i , with the consequence that the channel opens only when there is an outward electrochemical gradient, and the open channel will extrude H + from the cell. HVCN1 L and HVCN1 S exhibited similar ΔpH-dependent gating, both activating at potentials about 10 mV positive to V rev at symmetrical pH (SI Appendix, Fig. S2B ).
To compare gating kinetics, we used the perforated-patch voltage-clamp method, a more physiological configuration that preserves cytoplasmic contents. Comparison of the gating kinetics of HVCN1 L and HVCN1 S in unstimulated LK-35.2 cells (SI Appendix, Table S1) reveals that HVCN1 S channels opened more slowly, with a time constant of current turn-on, τ act , more than double that of HVCN1 L . Closing kinetics (τ tail ) and the position of the g H -V relationship did not differ significantly. Proton currents in phagocytes and other cells are greatly augmented by phosphorylation of the channel by PKC (8) . The enhanced gating response is stimulated effectively by the PKC activator PMA (phorbol myristate acetate) and is best studied using the perforated-patch configuration that preserves intracellular signaling pathways (9) . Fig. 2 illustrates families of proton currents in cells expressing HVCN1 L and HVCN1 S before and after PMA stimulation. In response to PMA, the currents turn on more rapidly and at more negative voltages and turn off more slowly, and the current amplitude is increased. Although HVCN1 L responds distinctly, the response of HVCN1 S was consistently more profound. Because there is a tendency early in each experiment for proton currents to become larger and activate at more negative voltages as the amphotericin in the pipette solution improves electrical access to the cell membrane, and as pH i is clamped to 7.0 by the applied NH 4 + gradient (9, 10), the PMA response may be exaggerated if measurements are made before complete equilibration. A crucial quantitative control is to reverse the effects of PMA using the PKC inhibitor GF 109203X (GFX). The reversal of enhanced gating by GFX in both representative cells in Fig. 2 was complete, validating the responses.
SI Appendix, Fig. S3 , shows normalized g H -V relationships after the PMA response and after GFX treatment in all cells studied expressing HVCN1 L or HVCN1 S . This comparison is more informative than control vs. PMA for reasons just discussed and because some cells were spontaneously active, as judged by GFX reversal being greater than the initial response to PMA. A possible spurious explanation for the greater PMA responsiveness of HVCN1 S is that HVCN1 L might have a greater tendency to activate spontaneously. SI Appendix, Fig. S3 , does not support this view, verifying that HVCN1 S is indeed more responsive.
SI Appendix, Fig. S4 , summarizes the magnitude of the changes in four kinetic parameters of HVCN1 gating resulting from PMA and GFX treatment of cells expressing the two isoforms. For each parameter, the PMA response was significantly greater in HVCN1 S than in HVCN1 L . Also for each parameter, GFX reversed the PMA response completely. In summary, HVCN1 S channels exhibit a more profound response to phosphorylation than do HVCN1 L channels.
Because B cells from CLL patients have higher-than-normal levels of HVCN1 S , their responsiveness might be enhanced. B cells from CLL patients and normal controls were studied by perforated-patch voltage clamp (n = 4 and 3, respectively), confirming that both CLL and normal B cells had proton currents that responded to PMA and GFX. Interestingly, CLL cells, which have a variable mixture of HVCN1 S and HVCN1 L (SI Appendix, Table S3 ), exhibited enhanced gating responses comparable with those of LK35.2 cells expressing HVCN1 S exclusively (SI Appendix, Fig. S5 ), indicating that HVCN1 S prevails in the response.
Identification of HVCN1 S Phosphorylation Site. Two predicted highprobability PKC-δ phosphorylation sites exist in the N terminus of HVCN1 L (11), Thr 29 and Ser 97 . We reported previously that both sites were phosphorylated after PMA exposure, but only Thr 29 contributed detectably to the enhanced gating response of HVCN1 L channels (11) . Because the lack of the first 20 amino acids of the N terminus might result in different protein folding or architecture, it was important to examine the contribution of both corresponding sites in HVCN1 S , namely Thr 9 and Ser 77 . We generated mutants that lacked one (T9A and S77A) or both (T9A/S77A) putative phosphorylation sites.
Cells with the T9A mutation (n = 9) and the double mutant T9A/S77A (n = 5) did not respond detectably to either PMA or GFX (SI Appendix, Fig. S6 ), implicating Thr 9 as crucial to the responses. In contrast, cells expressing the S77A mutant did respond to PMA and to GFX. Mean changes in parameter values are given in SI Appendix, Table S2 . Therefore, the key residue in the PMA response is Thr 9 (HVCN1 S ), the equivalent of Thr 29 in HVCN1 L channels (11) . Any participation of Ser 77 (HVCN1 S ) or Ser 97 (HVCN1 L ) in the enhanced gating response was below our ability to detect it.
Intriguingly, T9A cells studied before stimulation exhibited ninefold faster activation and a 24-mV more negative V threshold than did unstimulated HVCN1 S cells (SI Appendix, Table S1 ), resembling enhanced gating mode behavior. We reanalyzed data from analogous mutations studied previously in the full-length channel (11) and found that T29A also exhibited "enhanced gating" in unstimulated cells (SI Appendix, Table S1 ). Unstimulated "phosphomimetic" T29D cells exhibited weaker enhanced gating than T29A. Evidently, this Thr position is a potent determinant of gating kinetics. Together, these results suggest that phosphorylation of Thr 29 in HVCN1 L or Thr 9 in HVCN1 S produces enhanced gating by a mechanism not simply involving the negative charge provided by the phosphate group. However, we cannot rule out Fig. 2 . HVCN1 S responds more strongly to PMA stimulation than HVCN1 L . Perforated-patch voltage clamp was used to evaluate the electrophysiological properties of the two HVCN1 isoforms. Families of currents in 10-mV increments up to 70 mV from V hold = −40 mV are shown in representative LK35.2 cells expressing HVCN1 L (A) or HVCN1 S (B) before stimulation, after application of the PKC activator PMA, and after inhibition of PKC by GF 109203X (GFX). Between the families are superimposed currents obtained during test pulses to 60 mV (for HVCN1 L ) or 40 mV (for HVCN1 S ) applied at 30-s intervals before and after addition of PMA or GFX to the bath solution. (C and D) Proton conductancevoltage relationships, g H -V. The current amplitude was determined by extrapolating a single exponential fitted to the rising current, and g H was calculated from the current using V rev measured in each solution. Measurements were made in symmetrical pH 7.0 solutions containing 50 mM NH 4 + to clamp pH i (9) .
the possibility that these mutations alter gating through a mechanism unrelated to that elicited by phosphorylation. Because HVCN1 S responded more strongly to PKC phosphorylation and the effect was mediated by phosphorylation of Thr 9 exclusively, we speculated that it could reflect increased phosphorylation of this residue. Indeed, our in vitro kinase assay showed that overall phosphorylation of wild-type HVCN1 S was significantly higher than for wild-type HVCN1 L (Fig. 3 , Left, WT lanes). To assess phosphorylation of the critical PKC site mediating the enhanced-gating response, we carried out the same experiment with T29A (T9A for HVCN1 S ), S97A (S77A for HVCN1 S ), and T29A/S97A (T9A/S77A for HVCN1 S ) mutants. As shown in Fig. 3 , phosphorylation of the T9A mutant was reduced as much as for the T29A one, confirming that this Thr is phosphorylated by PKC in both isoforms. The analysis of the other PKC site mutant, S97A (S77A for HVCN1 S ), and double mutants indicated a further reduction in overall phosphorylation, as we reported previously for HVCN1 L (11) , suggesting that Ser is also phosphorylated by PKC. However, as before, the patchclamp experiments (SI Appendix, Fig. S6 and Table S1 ) indicated that phosphorylation of Thr 9 alone is responsible for the enhancement of HVCN1 S proton currents. HVCN1 S Has a Weaker Association with the BCR than Does HVCN1 L .
We found previously that HVCN1 was associated with the BCR in both normal and malignant B cells (3) . The association causes HVCN1 to be internalized together with the BCR after its stimulation, an event that downregulates HVCN1 expression at the cell surface (3) . Because the intracellular domains are likely to be the regions mediating the association with the BCR, we investigated if HVCN1 S behaved differently from HVCN1 L . We overexpressed both isoforms in the B lymphoma cell line A20 D1.3 and assessed their expression at steady state and after BCR stimulation with a F(ab′) 2 anti-IgM. Cells expressed similar levels of HVCN1, IgM, and the BCR coreceptor CD79B (SI Appendix, Fig. S7 A-C). We did not note significant differences in the pattern of expression of the two isoforms at steady state. Importantly, however, upon BCR stimulation, the extent of HVCN1 internalization for the two isoforms appeared different (Fig. 4A) . Quantification of the immunofluorescence staining showed a significantly larger percentage of internalized HVCN1 in cells expressing HVCN1 L compared with HVCN1 S (36 vs. 25%, Fig. 4A, Upper graph) . Furthermore, the extent of colocalization with IgM was also reduced from 0.562 to 0.407 ( Fig. 4A , Lower graph). Diminished HVCN1 S internalization was not due to reduced IgM internalization, which was actually increased, compared with cells overexpressing HVCN1 L (SI Appendix, Fig.  S7D ). These data indicate that HVCN1 S association with the BCR is different and that this results in increased localization of proton channels at the plasma membrane.
To determine the reason for the different association of HVCN1 isoforms with the BCR, we carried out a coimmunoprecipitation (co-IP) with an anti-CD79B and the reciprocal experiment with an anti-myc (for the myc-tagged HVCN1 isoforms). As shown in Fig. 4B , interaction of HVCN1 S with CD79B was indeed significantly weaker with both co-IP assays. The differences between the two antibodies are likely due to differences in the efficiency of pull down (with the anti-myc being more efficient than the anti-CD79B). Overall, these data show that the first 20 amino acids present in HVCN1 L are critical for the association with the BCR and that their absence in HVCN1 S results in greater expression of this isoform at the plasma membrane after BCR stimulation. HVCN1 S Expression Is Enriched in CLL Cells. Given the increased expression of HVCN1 S in B-cell lines and in CLL samples (Fig. 1A) , combined with its ability to mediate stronger proton currents (Fig. 2) , we investigated whether its expression could have an impact on CLL disease progression. To this end, we analyzed the expression of HVCN1 S in a cohort of 76 samples of peripheral Fig. 3 . HVCN1 S is phosphorylated more by PKC-δ than HVCN1 L . PKC-δ in vitro kinase assay showing phosphorylation of HVCN1 L and HVCN1 S wild type ("WT"), single mutants T29A ("29") or T9A for HVCN1 S ("9"), S97A ("97") or S77A for HVCN1 S ("77"), and double mutants T29A/S97A and T9A/ S77A for HVCN1 S ("DM"). The assay was carried out with recombinant HVCN1 L and HVCN1 S expressed in HEK293T cells and immunoprecipitated with an anti-myc antibody. Cells transfected with an empty vector ("EV") were used as negative control. The myc immunoblot indicates loading. Bars represent the densitometry analysis of the 32 P-HVCN1 versus myc-HVCN1 of three independent experiments (mean ± SEM). NS, not significant. blood CLL cells with annotated clinical data. Details of the patients' characteristics are reported in SI Appendix , Table S3 . The samples investigated showed variable expression of both isoforms, with an average ratio of HVCN1 S to HVCN1 L of 0.52 ± 0.034 (mean ± SE). As shown in Fig. 1A , HVCN1 S was markedly higher in CLL than in primary B cells from healthy donors, in which HVCN1 S is barely detectable. Given the wide range of HVCN1 S expression in CLL cells, we split samples in two groups, one with a ratio of HVCN1 S /HVCN1 L below the median value of 0.477 (i.e., with lower expression of HVCN1 S ) and one with higher HVCN1 S expression (above the median). A Kaplan-Meier curve for overall survival showed that patients with higher expression of HVCN1 S had reduced overall survival, although differences did not reach statistical significance (SI Appendix, Fig.  S8 ). We further analyzed the data specifically for the two main subgroups of CLL patients: those presenting a mutated variable region in the BCR heavy chain (IGHV) and those with an unmutated IGHV. Given the small number of samples for which we knew the mutation status (SI Appendix, Fig. S8 and Table S3 ), it was not surprising that differences did not reach statistical significance; nonetheless, higher expression of HVCN1 S tended to correlate with a poorer outcome in both groups.
HVCN1 S Expression Results in Stronger BCR-Dependent Signaling,
Proliferation, and Chemokine-Dependent Migration. To establish if HVCN1 S could confer a growth advantage to malignant B cells, we first assessed BCR-dependent signaling in A20 D1.3 cells transduced with empty vector (EV), HVCN1 L , and HVCN1 S . As shown in Fig. 5A , the presence of HVCN1 S resulted in more prolonged activation of the extracellular signal-regulated kinase (Erk), which is responsible for the upregulation of several antiapoptotic proteins in CLL cells (12) . Furthermore, to determine if the two proton channel isoforms regulated cell proliferation, we measured the extent of EdU incorporation, a nucleoside analog included in nascent DNA. Interestingly, only HVCN1 S provided a significant advantage compared with EV cells (Fig. 5B) .
Another important property of CLL cells is the ability to respond to the chemokine CXCL12 [chemokine (C-X-C motif) ligand 12], which affects their migration, homing, and survival (13) . Because HVCN1 was shown to regulate migration of breast (5) and colorectal cancer cells (6), we set out to characterize if HVCN1 isoforms affected chemokine-dependent migration in a B-cell setting. As Fig. 5C shows, both HVCN1 L and HVCN1 S expression resulted in increased migration to CXCL12; however, only HVCN1 S resulted in a significant advantage. Taken together, these data indicate that HVCN1 S promotes malignant B-cell survival through enhanced proliferation and migration.
Discussion
Only one proton channel gene has been identified in any species. However, the human gene can generate two different isoforms, HVCN1 L and HVCN1 S (3). In this paper, we confirmed the existence of alternative splicing variants as reported in the GenBank database, presenting evidence that translation of HVCN1 S starts at an alternative ATG. The resulting protein is 20 amino acids shorter at the N terminus, as confirmed here by immunoblotting with an antibody raised against the first 20 amino acids of full-length HVCN1 (HVCN1 L ). Compared with peripheral B cells from healthy donors, B-cell lines and CLL cells showed increased expression of total HVCN1 due to an upregulation of HVCN1 S . Higher levels of HVCN1 S tended to correlate with decreased overall survival in a cohort of 76 blood samples from CLL patients. Given the wide range of expression of HVCN1 S in CLL and the limited number of samples analyzed, it would be necessary to screen a much larger panel of samples to determine if this trend is significant. This would be particularly interesting for the mutated CLL subgroup because these patients have a more favorable prognosis overall; however, some still present more aggressive disease, and markers to identify this subpopulation are lacking.
Comparison of their electrophysiological properties revealed that HVCN1 S channels open about twice as slowly as HVCN1 L channels. A more profound difference was seen in response to stimulation by PMA. Agonists that activate PKC strongly amplify the proton conductance in many human and mammalian cells (8, 9, (14) (15) (16) (17) (18) , a phenomenon called "enhanced gating." Although both isoforms responded to PMA, the HVCN1 S response was significantly greater. This differential responsiveness enables cells to modulate proton channel activity by preferential expression of HVCN1 S or HVCN1 L isoforms. That the PMA response of CLL cells resembled that of LK35.2 cells expressing exclusively HVCN1 S reveals that, in a mixture of isoforms, HVCN1 S will dominate due to its lower V threshold .
The distinct gating of the two isoforms HVCN1 S and HVCN1 L that differ only in the first 20 amino acids of the N terminus emphasizes the importance of this intracellular domain in modulating gating kinetics. Proton channels are thought to open as a result of outward movement of the S4 transmembrane helix (19) (20) (21) . Being an extension of the S4 helix, the C terminus affects gating directly (22) . Nevertheless, gating kinetics is modulated drastically (i) in the enhanced gating mode by phosphorylation of Thr 29 (11), (ii) by the point mutation T9A in HVCN1 S or T29A in HVCN1 L (SI Appendix, Table S1 ), and (iii) in the naturally occurring mutation M91T (23), all of which are localized to the N terminus.
Because T9A and T9A/S77A mutants failed to respond to PMA or GFX, enhanced gating of HVCN1 S is evidently mediated entirely by phosphorylation of Thr 9 . This residue is equivalent to Thr 29 , the key phosphorylation site producing enhanced gating in HVCN1 L (11) . Here we show that phosphorylation of Thr 9 and overall phosphorylation is greater in HVCN1 S than in HVCN1 L , suggesting that the loss of the first 20 amino acids facilitates phosphorylation of this residue. Additionally, the mechanism by which phosphothreonine orchestrates enhanced gating may be modified in HVCN1 S . Whether the two isoforms are phosphorylated at steady state in tumor B cells will depend upon expression and activation of PKC in these cells. Because PKC was expressed and activated in the great majority of CLL samples investigated (SI Appendix, Table S3 ), we believe constitutive phosphorylation of proton channels in CLL cells to be highly likely.
Furthermore, we present evidence that HVCN1 S has a weaker association with the BCR, which results in greater expression at the plasma membrane and reduced internalization upon BCR stimulation. Evidently, the first 20 amino acids of HVCN1 are important for association with the BCR. It will be interesting to investigate which residues in HVCN1 are involved in this interaction and whether there is a direct association with the BCR complex (either the Ig or the coreceptors CD79A and CD79B) or if additional scaffolding proteins are involved. Malignant B cells such as CLL cells are stimulated through their BCR in the tumor microenvironment, and each round of stimulation normally results in BCR internalization (4) . That tumor B cells upregulate an isoform of HVCN1 that remains preferentially at the plasma membrane after BCR stimulation suggests that these cells might find plasma membrane expression of HVCN1 S beneficial to their growth. This is corroborated by the advantage in BCR-dependent Erk activation, proliferation, and chemokine-dependent migration conferred by HVCN1 S . Higher levels of HVCN1 expression correlate with metastatic tendency and poor prognosis in breast cancer (5) and colorectal cancer (6) although the isoform involved has not been reported.
Overall, our data show the existence of a shorter isoform of HVCN1 with enhanced gating responses that is specifically enriched in malignant B cells. The enhanced gating of HVCN1 S produces larger proton currents in CLL cells that may contribute to the pathology, as suggested by stronger BCR signaling, increased cell proliferation, and chemokine response provided by HVCN1 S expression.
Materials and Methods
Cell Lines and Plasmids. The mouse B lymphoma cell lines LK35.2 HyHEL10 (IgG2a, κ-chain; H-2 kxd ) and A20 D1.3 (IgG2a, κ-chain; H-2 d ) overexpressing recombinant IgM receptors were a gift from F. Batista (London Research Institute, London). The cells were transduced with MigRI retroviral vectors coding for myc-tagged HVCN1 L or HVCN1 S . T29A (T9A for HVCN1 S ), S97A (S77A for HVCN1 S ), and T29A/S97A (T9A/S77A for HVCN1 S ) mutants were generated using a QuikChange site-directed mutagenesis kit (Stratagene). The retroviral particles were produced in the Phoenix α packaging cell line as described elsewhere (11) .
Phosphorylation Assay. HEK293T cells were transfected by Ca 2+ phosphate with myc-tagged HVCN1 L , HVCN1 S , and mutant plasmids. Forty-eight hours after transfection, cells were lysed in 20 mM Hepes, 1% Triton X-100, 137 mM NaCl, 2.5 mM β-glycerophosphate, 1 mM Na 3 VO 4 , 2 mM EDTA, and proteases inhibitors (Sigma Aldrich). One milligram of proteins was immunoprecipitated with anti-myc tag antibody (9B11, Cell Signaling Technology) conjugated to protein-G Sepharose beads for 1 h. After washing with lysis buffer, beads were incubated in 40 μL kinase assay buffer [20 mM Hepes, 1 mM EGTA, 0.4 mM EDTA, 5 mM MgCl 2 , 0.1 mM CaCl 2 , 0.05 mM DTT, 0.1 mg/mL phosphatidylserine, 0.01 mg/mL diacylglycerol, 2.5 mM β-glycerophosphate, 1 μM PMA, 100 nM PKC-δ (Millipore), 100 μM cold ATP, and 10 μCi of [γ-32 P]ATP (Perkin-Elmer)] for 20 min at 30°C. The reaction was stopped by resuspending beads in 2× Laemmli sample buffer. Samples were then separated by SDS/PAGE, transferred to a nitrocellulose membrane, and exposed to X-ray films. Membranes were immunoblotted with anti-myc antibody to determine loading.
Electrophysiology. Whole-cell or perforated-patch variants of the patch-clamp technique were carried out as described in detail previously (24) . Perforatedpatch studies included ∼225 μM amphotericin B in the pipette to permeabilize the patch membrane, and 50 mM NH 4 + to clamp pH i to pH o . For whole-cell studies, the main pipette solution (also used externally) contained (in mM) 130 TMACH 3 SO 3 , 2 MgCl 2 , 2 EGTA, and 80 MES, titrated to pH 5.5 with ∼20 tetramethylammonium hydroxide (TMAOH). Bath solutions at pH 7.0 had (in mM) 90 TMACH 3 SO 3 , 3 CaCl 2 , 1 EGTA, 100 N,N-Bis-(2-hydroxyethyl)-2aminoethanesulfonic acid (BES), and 36-40 TMAOH. When pH was varied, the following buffers with pK a near the desired pH were used: Homopipes for pH 4.6, MES for pH 5.5-6.0, BisTris for pH 6.5, Hepes for pH 7.5, and Tricine for pH 8.0. Experiments were done at 21°C or at room temperature (20-25°C) .
No leak correction has been applied to current records.
Patch-Clamp Studies of CLL and Healthy B Cells. Cells were shipped frozen on dry ice. After thawing, cells were suspended in RPMI with serum, centrifuged at 1,100 × g for 5 min, and resuspended in a small volume (1-2 mL) of RPMI with serum. For each of the first three parameters, the relative change is plotted so that the effect increases relative to 1.0 (dashed reference line); the ratio for  act is (control/PMA), for  tail is (PMA/control), for g H,max is (control/PMA). Similarly, for GFX reversal, the ratio for  act is (GFX/PMA), for  tail is (PMA/GFX), for g H,max is (GFX/PMA). For the shift in V threshold the values show the absolute magnitude of the negative shift produced by PMA and the positive shift produced by GFX. For each parameter, the HVCN1 S response is significantly greater than the HVCN1 L response (*p<0.05, **p<0.01). For each parameter, the reversal by GFX is not significantly different from the effect of PMA.
In many human and mammalian cells, stimulation by agonists that act through activation of PKC results in strong amplification of the proton conductance (1-8), a phenomenon that has been called "enhanced gating." Enhanced gating encompasses a predictable constellation of changes in the properties of proton channels (described in -5 -this table); however, there are two subtypes of enhanced gating. In the full enhanced gating mode V threshold shifts by -30 to -40 mV,  act speeds typically 3-5-fold,  tail slows up to 3-5 fold, and g H,max increases by 2-4-fold. The full response occurs in cells with a high level of NADPH oxidase (NOX) activity; agents that activate NOX also produce enhanced gating of HVCN1 (9) . Cells exhibiting a full response include human eosinophils (1, 2, 5, 10), neutrophils (3), monocytes (7), PLB-985 cells (11) , and sperm (4), and mouse granulocytes (5), osteoclasts (6) , and perhaps dendritic cells (12) . A modified degree of enhanced gating occurs in cells lacking NOX activity; typically the g H -V relationship shifts by -20 mV or less and  tail slows little or not at all (13) . The PMA response observed here in cells expressing HVCN1 S fits this pattern precisely, with a 5fold speeding of  act , and a 3-fold increase in g H,max , but  tail slowed less than 2-fold, and the g H -V relationship shifted only -20 mV. Other cells that exhibit a partial response include human neutrophils from CGD patients lacking gp91 phox , PLB-985 cells with gp91 phox knocked out (11) , and human basophils (8) . The PMA response observed here in HVCN1 S is consistent with the low level of ROS production by LK35.2 cells.
-6 - S6 . The responses to PMA and GFX in three mutants of HVCN1 S . The T9A mutant of HVCN1 S does not respond to PMA or GFX. The S77A mutant of HVCN1 S responds distinctly to PMA and GFX, whereas the double mutant T9A/S77a also fails to respond.
These results implicate Thr 9 as essential to the enhanced gating response. Families of currents in the same cell during identical voltage pulses before stimulation, after PMA, and after GFX treatment are shown for representative cells. Each cell was held at -40 mV and pulses were applied in 10 mV increments up to the indicated voltage. Note the rapid activation of cells with the T9A mutation (single or double).
-8 - Relative changes in each parameter are given (i.e., 1.0 means no response). As in Fig.   S5 , the ratio for  act is (control/PMA), for  tail is (PMA/control), for g H,max is (control/PMA).
For GFX reversal, the ratio for  act is (GFX/PMA), for  tail is (PMA/GFX), for g H,max is (GFX/PMA). V threshold values are the absolute magnitude of the negative shift produced by PMA and the positive shift produced by GFX. None of the responses differs significantly from HVCN1 S responses, except for the GFX reversal of V threshold , which was smaller for S77A. 
